Clinical trials
Phase 2 Uterine Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 4 |
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 8 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
| Terminated | 11 |
| Recruiting | 7 |
| Unknown status | 5 |
| Active, not recruiting | 4 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 7 |
| Dana-Farber Cancer Institute | 3 |
| Eli Lilly and Company | 3 |
| Montefiore Medical Center | 3 |
| Abramson Cancer Center at Penn Medicine | 2 |
| Novartis Pharmaceuticals | 2 |
| University of Alabama at Birmingham | 2 |
| Amgen | 1 |
| Bay Area Gynecology Oncology | 1 |
| Denise Fabian | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Neoplasms | 56 |
| Endometrial Neoplasms | 19 |
| Ovarian Neoplasms | 18 |
| Uterine Cervical Neoplasms | 15 |
| Breast Neoplasms | 8 |
| Colorectal Neoplasms | 5 |
| Fallopian Tube Neoplasms | 5 |
| Neoplasms | 5 |
| Vulvar Neoplasms | 5 |
| Genital Neoplasms, Female | 4 |
Trials
Showing 1 to 25 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.